Epsilogen
Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Epsilogen has raised €37M across 1 funding round from 5 investors, most recently a Series B round in Mar 2022. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKepsilogen.com ↗
Total raised
€37M
€36,907,677
Funding rounds
1
Investors
5
distinct backers
Active since
2022-03
latest 2022-03
Funding by year
EUR raised per yearEpsilogen — funding by year — interactive chart.
Data table
| Epsilogen — funding by year | |
|---|---|
| 2022 | €37M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-03-02 | Series B | €37M | 3B Future Health Fund,British Patient Capital,Caribou Property Limited,Novartis Venture Fund,Schroders Capital | View deal → |